- In recent months, Guardant Health has gained US FDA approval for an updated Guardant360 liquid biopsy test, seen its Shield colorectal cancer screening test included in American Cancer Society guidelines, and reported first-quarter results that exceeded earlier expectations on test volumes and coverage.
- Together, these regulatory, clinical, and commercial milestones highlight growing acceptance of Guardant’s blood-based cancer tests across both oncology care and population screening pathways.
- Next, we’ll examine how Shield’s inclusion in American Cancer Society colorectal screening guidelines may influence Guardant Health’s broader investment narrative.
AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
Guardant Health Investment Narrative Recap
To own Guardant Health, you need to believe blood based cancer testing can support a large, durable business while the company manages heavy investment and ongoing losses. The Shield guideline inclusion directly supports the key near term catalyst of broader screening adoption, but does not resolve the biggest risk around sustained cash burn and potential future financing needs.
Among the recent updates, the American Cancer Society’s decision to include Shield in its colorectal cancer screening guidelines is most relevant here, because it speaks directly to payer and physician acceptance. This recognition could influence how quickly Shield testing volumes and reimbursement evolve, which sits at the heart of both the upside case and concerns about pressure on margins and returns.
Yet even as Shield gains guideline support, investors should be aware that...
Read the full narrative on Guardant Health (it's free!)
Guardant Health's narrative projects $2.5 billion revenue and $3.9 million earnings by 2029.
Uncover how Guardant Health's forecasts yield a $171.08 fair value, a 5% upside to its current price.
Exploring Other Perspectives
Before this news, the most cautious analysts expected about US$1.7 billion revenue by 2029 and still questioned profitability, so Shield’s guideline win may lead them to rethink how quickly...
Explore 4 other fair value estimates on Guardant Health - why the stock might be worth less than half the current price!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Guardant Health research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
- Our free Guardant Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Guardant Health's overall financial health at a glance.
Seeking Other Investments?
Opportunities like this don't last. These are today's most promising picks. Check them out now:
- Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 17 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
- We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com